Among the γδ T cell subsets, Vγ9Vδ2 T cells have demonstrated notable antitumor activity against GBM through mechanisms such as perforin/granzyme-mediated lysis and NKG2D-dependent recognition of ligands including ULBP and MIC [15,59,60]. This evidence concerns the gene KLRK1 and glioblastoma.